Literature DB >> 24336338

Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy.

Naoshi Nishina1, Jun Kikuchi, Misato Hashizume, Keiko Yoshimoto, Hideto Kameda, Tsutomu Takeuchi.   

Abstract

Entities:  

Keywords:  Cytokines; DMARDs (biologic); Disease Activity; Rheumatoid Arthritis; Treatment

Mesh：

Substances：

Year:  2013        PMID： 24336338     DOI： 10.1136/annrheumdis-2013-204137

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  10 in total

Review 1.  Lessons From Transcriptome Analysis of Autoimmune Diseases.

Authors:  Yasuo Nagafuchi; Haruyuki Yanaoka; Keishi Fujio
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

Review 2.  Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review.

Authors:  Michitaro Hayakawa; Keisuke Izumi; Misako Higashida-Konishi; Mari Ushikubo; Masako Tsukamoto; Kumiko Akiya; Kazuhiro Araki; Hisaji Oshima
Journal:  Rheumatol Int       Date:  2018-10-24       Impact factor: 2.631

3.  Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.

Authors:  Fang Chen; David T Teachey; Edward Pequignot; Noelle Frey; David Porter; Shannon L Maude; Stephan A Grupp; Carl H June; Jan J Melenhorst; Simon F Lacey
Journal:  J Immunol Methods       Date:  2016-04-03       Impact factor: 2.303

4.  Low baseline interleukin-17A levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients.

Authors:  Sang Jin Lee; Won Park; Sung Hwan Park; Seung-Cheol Shim; Han Joo Baek; Dae-Hyun Yoo; Hyun Ah Kim; Soo Kon Lee; Yun Jong Leee; Young Eun Park; Hoon-Suk Cha; Jin Kyun Park; Eun Young Lee; Eun Bong Lee; Yeong Wook Song
Journal:  J Immunol Res       Date:  2015-04-02       Impact factor: 4.818

5.  Pretreatment Prediction of Individual Rheumatoid Arthritis Patients' Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers.

Authors:  Kazuko Uno; Kazuyuki Yoshizaki; Mitsuhiro Iwahashi; Jiro Yamana; Seizo Yamana; Miki Tanigawa; Katsumi Yagi
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

6.  Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).

Authors:  Keisuke Izumi; Yuko Kaneko; Misato Hashizume; Keiko Yoshimoto; Tsutomu Takeuchi
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

7.  Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission.

Authors:  Hideto Kameda; Ayako Hirata; Takaharu Katagiri; Yuto Takakura; Yuki Inoue; Sayaka Takenaka; Hideki Ito; Kennosuke Mizushina; Takehisa Ogura
Journal:  Sci Rep       Date:  2021-03-25       Impact factor: 4.379

Review 8.  Toward Overcoming Treatment Failure in Rheumatoid Arthritis.

Authors:  Zhuqian Wang; Jie Huang; Duoli Xie; Dongyi He; Aiping Lu; Chao Liang
Journal:  Front Immunol       Date:  2021-12-23       Impact factor: 7.561

9.  Neutrophil count reduction 1 month after initiating tocilizumab can predict clinical remission within 1 year in rheumatoid arthritis patients.

Authors:  Tomoya Nakajima; Ryu Watanabe; Motomu Hashimoto; Koichi Murata; Kosaku Murakami; Masao Tanaka; Hiromu Ito; Wataru Yamamoto; Koji Kitagori; Shuji Akizuki; Ran Nakashima; Hajime Yoshifuji; Koichiro Ohmura; Shuichi Matsuda; Akio Morinobu
Journal:  Rheumatol Int       Date:  2021-07-09       Impact factor: 3.580

10.  Predicting treatment response to IL6R blockers in rheumatoid arthritis.

Authors:  Bako Nouri; Nisha Nair; Anne Barton
Journal:  Rheumatology (Oxford)       Date:  2020-12-01       Impact factor: 7.580
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.